Persistent pain, which is poorly treated and estimated to afflict one third of the world's population, is largely mediated by the sensitization of nociceptive neurons. This sensitization involves de novo gene expression to support biochemical and structural changes required to maintain amplified pain signaling that frequently persists even after injury to tissue resolves. While transcriptiondependent changes in gene expression are important, recent work demonstrates that activity-dependent regulation of mRNA translation is key to controlling the cellular proteome and the development and maintenance of persistent pain. In this review, we highlight recent advances in translational regulation of gene expression in nociceptive circuits, with a focus on key signaling pathways and mRNA targets that may be tractable for the creation of next-generation pain therapeutics.
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Why Is Translational Control Important for Persistent Pain?
Dorsal root ganglion (DRG) and trigeminal ganglion (TG) neurons are remarkable structures, with a cell body located up to a meter away from the transduction mechanisms in nerve endings that innervate skin, muscles, and visceral organs. Approximately 50% of these neurons are nociceptive, meaning that they detect damaging or potentially damaging stimuli and transmit signals to the brain that are eventually perceived as pain. The traditional view of these neurons as static transmitters of information has been overturned in recent decades because numerous studies have demonstrated that injury and/or endogenous mediators are capable of fundamentally changing the neurochemical and electrophysiological phenotypes of these neurons, making them extraordinarily hyperexcitable as pain becomes persistent. This is a key feature of clinical pain disorders and has emerged as a major intervention point for pain therapeutics.
Why translational control? Changes in gene expression are key to nociceptor (see Glossary) plasticity and phenotypic alterations, but many of these changes evidently do not start at the cell body, because transcriptional changes and protein sorting to nerve endings are not rapid enough to explain this physiology. A solution that has emerged to solve this biological riddle is localized translation at nociceptor endings and/or along injured axons to control changes in gene expression. This solution is important because: (i) it explains how many endogenous painpromoting molecules induce long-lasting plasticity [1-10]; (ii) it is supported by findings from experimental pain models in humans that are best explained by localized translation regulation [11, 12] ; and (iii) it provides insight into the generation of ectopic activity after peripheral nerve injury [6, [13] [14] [15] [16] , which is a major driver of neuropathic pain. In this review, we summarize rapidly growing, recent literature that elucidates the intricacies of translational control in persistent pain and highlight new therapeutic opportunities.
Highlights
Persistent pain is largely mediated by the sensitization of nociceptive neurons. This sensitization relies on de novo gene expression to support biochemical and structural changes that maintain amplified pain signaling.
Nerve injury and peripheral inflammation stimulate local translation from pre-existing mRNAs in nociceptive sensory neurons. The newly synthesized proteins act locally to increase neuronal excitability or are transported to the cell body to activate transcriptional gene expression programs.
Eukaryotic initiation factor 4F (eIF4F) complex formation is a convergent point downstream of mammalian target of rapamycin (mTOR) and extracellular-signal-regulated kinase (ERK) signaling pathways to regulate capdependent translation and promote neuronal excitability, synaptic transmission, and pain. A cellular energy status sensor AMP-activated protein kinase (AMPK) emerges as an attractive target to normalize aberrant mRNA translation in pathological pain conditions. Metformin, an AMPK activator and US Food and Drug Administration (FDA)-approved antidiabetic drug, corrects abnormal mRNA translation and reverses enhanced neuronal excitability and pain hypersensitivity in a variety of animal models of chronic pain.
